Literature DB >> 27826139

NAFLD: The clinical and economic burden of NAFLD: time to turn the tide.

Manal F Abdelmalek1.   

Abstract

Year:  2016        PMID： 27826139     DOI： 10.1038/nrgastro.2016.178

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial.

Authors:  Vincent Wai-Sun Wong; Ruth Suk-Mei Chan; Grace Lai-Hung Wong; Bernice Ho-Ki Cheung; Winnie Chiu-Wing Chu; David Ka-Wai Yeung; Angel Mei-Ling Chim; Jennifer Wing-Yan Lai; Liz Sin Li; Mandy Man-Mei Sea; Francis Ka-Leung Chan; Joseph Jao-Yiu Sung; Jean Woo; Henry Lik-Yuen Chan
Journal:  J Hepatol       Date:  2013-04-23       Impact factor: 25.083

2.  Primary care practitioners survey of non-alcoholic fatty liver disease.

Authors:  Adnan Said; Veronika Gagovic; Kristen Malecki; Marjory L Givens; F Javier Nieto
Journal:  Ann Hepatol       Date:  2013 Sep-Oct       Impact factor: 2.400

3.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Authors:  Arun J Sanyal; Naga Chalasani; Kris V Kowdley; Arthur McCullough; Anna Mae Diehl; Nathan M Bass; Brent A Neuschwander-Tetri; Joel E Lavine; James Tonascia; Aynur Unalp; Mark Van Natta; Jeanne Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck
Journal:  N Engl J Med       Date:  2010-04-28       Impact factor: 91.245

4.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.

Authors:  Eduardo Vilar-Gomez; Yadina Martinez-Perez; Luis Calzadilla-Bertot; Ana Torres-Gonzalez; Bienvenido Gra-Oramas; Licet Gonzalez-Fabian; Scott L Friedman; Moises Diago; Manuel Romero-Gomez
Journal:  Gastroenterology       Date:  2015-04-10       Impact factor: 22.682

5.  Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.

Authors:  Konstantinos Kargiotis; Vasilios G Athyros; Olga Giouleme; Niki Katsiki; Evangelia Katsiki; Panagiotis Anagnostis; Chrysoula Boutari; Michael Doumas; Asterios Karagiannis; Dimitri P Mikhailidis
Journal:  World J Gastroenterol       Date:  2015-07-07       Impact factor: 5.742

6.  Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease.

Authors:  Manal F Abdelmalek; Ayako Suzuki; Cynthia Guy; Aynur Unalp-Arida; Ryan Colvin; Richard J Johnson; Anna Mae Diehl
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

7.  Practice patterns in NAFLD and NASH: real life differs from published guidelines.

Authors:  Mary E Rinella; Zurabi Lominadze; Rohit Loomba; Michael Charlton; Brent A Neuschwander-Tetri; Stephen H Caldwell; Kris Kowdley; Stephen A Harrison
Journal:  Therap Adv Gastroenterol       Date:  2016-01       Impact factor: 4.409

8.  The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.

Authors:  Zobair M Younossi; Deirdre Blissett; Robert Blissett; Linda Henry; Maria Stepanova; Youssef Younossi; Andrei Racila; Sharon Hunt; Rachel Beckerman
Journal:  Hepatology       Date:  2016-09-26       Impact factor: 17.425

Review 9.  Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study.

Authors:  Wenjing Sun; Hongli Cui; Ning Li; Yanling Wei; Shujie Lai; Yang Yang; Xinru Yin; Dong-Feng Chen
Journal:  Hepatol Res       Date:  2016-02-16       Impact factor: 4.288

10.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

Authors:  Matthew James Armstrong; Piers Gaunt; Guruprasad P Aithal; Darren Barton; Diana Hull; Richard Parker; Jonathan M Hazlehurst; Kathy Guo; George Abouda; Mark A Aldersley; Deborah Stocken; Stephen C Gough; Jeremy W Tomlinson; Rachel M Brown; Stefan G Hübscher; Philip N Newsome
Journal:  Lancet       Date:  2015-11-20       Impact factor: 79.321
  10 in total
  5 in total

1.  Foxo3a-dependent Bim transcription protects mice from a high fat diet via inhibition of activation of the NLRP3 inflammasome by facilitating autophagy flux in Kupffer cells.

Authors:  Yan Liu; Wenfeng Zhang; Xiaoling Wu; Jianping Gong
Journal:  Oncotarget       Date:  2017-05-23

2.  TM5441, a plasminogen activator inhibitor-1 inhibitor, protects against high fat diet-induced non-alcoholic fatty liver disease.

Authors:  Seon Myeong Lee; Debra Dorotea; Inji Jung; Tetsuo Nakabayashi; Toshio Miyata; Hunjoo Ha
Journal:  Oncotarget       Date:  2017-09-21

Review 3.  Nonalcoholic Fatty Liver Disease.

Authors:  Lingling Ding; Yvonne Oligschlaeger; Ronit Shiri-Sverdlov; Tom Houben
Journal:  Handb Exp Pharmacol       Date:  2022

4.  Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction.

Authors:  Michelle L Boland; Stephanie Oldham; Brandon B Boland; Sarah Will; Jean-Martin Lapointe; Silvia Guionaud; Christopher J Rhodes; James L Trevaskis
Journal:  World J Gastroenterol       Date:  2018-04-28       Impact factor: 5.742

5.  Protective Properties of FOXO1 Inhibition in a Murine Model of Non-alcoholic Fatty Liver Disease Are Associated With Attenuation of ER Stress and Necroptosis.

Authors:  Hao-Ran Ding; Zhen-Ting Tang; Ning Tang; Zheng-Yi Zhu; Han-Yi Liu; Chen-Yan Pan; An-Yin Hu; Yun-Zhen Lin; Peng Gou; Xian-Wen Yuan; Jia-Hui Cai; Chun-Long Dong; Jing-Lin Wang; Hao-Zhen Ren
Journal:  Front Physiol       Date:  2020-03-11       Impact factor: 4.566
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.